BRIEF SUMMARY BRIEF SUMMARY
4 CONTRAINDICATIONS
None.
4 CONTRAINDICATIONS
None.
PROMACTA (eltrombopag) tablets, for oral use PROMACTA (eltrombopag) tablets, for oral use
The following is a brief summary only; see full prescribing information for
complete product information.
The following is a brief summary only; see full prescribing information for
complete product information.
5 WARNINGS AND PRECAUTIONS 5 WARNINGS AND PRECAUTIONS
WARNING: RISK FOR HEPATOTOXICITY
PROMACTA may cause hepatotoxicity. PROMACTA, in combination
with interferon and ribavirin in patients with chronic hepatitis C,
may increase the risk of hepatic decompensation [see Warnings and
Precautions ( 5. 1, 5. 2)].
